Provided herein are peptide inhibitors of the interaction between End Binding Protein 3 (EB3) and Inositol 1,4,5-Trisphosphate Receptor Type 3 (IP3R3). Also provided are methods and materials for treating lung injury, including acute lung injury, which may include hyperpermeability of lung vessels, vascular leakage, the development of edema, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion.

Komarova; Yulia A.

Saqib; Uzma

Vogel; Stephen M.

Malik; Asrar B.

THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

The Board of Trustees of the University of Illinois

The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.

Korea Institute of Oriental Medicine

Pharmaceutical composition for preventing or treating angioedema, containing extract of peony root or mixture of peony root and licorice as active ingredient

The present invention relates to the therapeutic application of the Kazal-type serine protease inhibitor Infestin or domains thereof or modified Kazal-type serine protease inhibitors based on Infestin homologs, which prevent the formation and/or stabilization of three-dimensional arterial or venous thrombi by interfering with proteins involved in activation of the so-called intrinsic coagulation pathway. The present invention also relates to the use of Kazal-type serine protease inhibitors or fragments thereof or modified Kazal-type serine protease inhibitors in the treatment or prophylaxis of a condition or disorder related to arterial thrombus formation, i.e. stroke or myocardial infarction, inflammation, complement activation, fibrinolysis, angiogenesis and/or diseases linked to pathological kinin formation such as hypotonic shock, edema including hereditary angioedema, bacterial infections, arthritis, pancreatitis, or articular gout, Disseminated Intravasal Coagulation (DIC) and sepsis.

CSL Behring GmbH

Therapeutic application of Kazal-type serine protease inhibitors

angioedema

edema

angioedema/edema

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Peptide compositions and methods for treating lung injury, asthma, anaphylaxis, angioedema, systemic vascular permeability syndromes, and nasal congestion

Pharmaceutical composition for preventing or treating angioedema, containing extract of peony root or mixture of peony root and licorice as active ingredient

Therapeutic application of Kazal-type serine protease inhibitors

Najkompletnija baza ljekovitog bilja potpomognuta naukom